-$0.17 EPS Expected for Cyclacel Pharmaceuticals Inc (CYCC) This Quarter

Equities analysts expect Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) to report earnings of ($0.17) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Cyclacel Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.15). Cyclacel Pharmaceuticals posted earnings per share of ($0.91) during the same quarter last year, which would suggest a positive year over year growth rate of 81.3%. The company is expected to issue its next earnings results on Thursday, November 8th.

On average, analysts expect that Cyclacel Pharmaceuticals will report full-year earnings of ($0.63) per share for the current year, with EPS estimates ranging from ($0.71) to ($0.55). For the next year, analysts expect that the business will post earnings of ($0.80) per share, with EPS estimates ranging from ($0.91) to ($0.68). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04).

Several research firms have recently commented on CYCC. Zacks Investment Research upgraded shares of Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 8th. HC Wainwright set a $7.00 price target on shares of Cyclacel Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 10th. LADENBURG THALM/SH SH began coverage on shares of Cyclacel Pharmaceuticals in a report on Friday, September 7th. They issued a “buy” rating and a $6.25 price target for the company. Finally, Roth Capital began coverage on shares of Cyclacel Pharmaceuticals in a report on Wednesday, September 5th. They issued a “buy” rating and a $8.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $5.75.

Shares of NASDAQ:CYCC traded up $0.03 during trading hours on Friday, hitting $1.38. The company’s stock had a trading volume of 30,057 shares, compared to its average volume of 113,231. Cyclacel Pharmaceuticals has a 52 week low of $1.28 and a 52 week high of $2.25.

An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC increased its position in shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 513.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 76,500 shares during the quarter. Renaissance Technologies LLC owned about 0.76% of Cyclacel Pharmaceuticals worth $130,000 as of its most recent SEC filing. Institutional investors and hedge funds own 5.61% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

Featured Article: Growth Stocks

Get a free copy of the Zacks research report on Cyclacel Pharmaceuticals (CYCC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply